Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada.

Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive and off all therapy.

These results come from a population with substantial prior treatment. Patients had received a median of four prior lines of therapy, and 66% had received at least four. All had previously received platinum chemotherapy, 77% had received bevacizumab and 57% had received a PARP inhibitor. Nearly three-quarters had platinum-resistant or refractory disease, meaning their cancer had progressed during platinum treatment or returned within six months of it.

“In recurrent ovarian cancer, conventional checkpoint immunotherapy has rarely produced lasting benefit, particularly after the disease stops responding to platinum chemotherapy,” said Rebecca L. Porter, MD, of Dana-Farber Cancer Institute, who presented the data. “What stands out with longer follow-up is the survival plateau in patients who had already received multiple treatments. That pattern suggests that a different approach to activating the immune system may offer some patients lasting benefit, even when treatment options have narrowed.”

Three-year follow-up findings

Overall efficacy results (n=35)

• Overall survival (OS): Estimated survival was 48% at both two and three years. Median OS was 14.8 months.
• Objective response rate (ORR): 23% of patients (8/35) had a response, including one complete response and seven partial responses.
• Duration of response: Responses lasted a median of 9.7 months.
• Clinical benefit: 31% of patients (11/35) had a response or stable disease lasting at least 24 weeks.
• Alive and off treatment: At last follow-up, 25% (11 of all 44 patients who received at least one dose of treatment) were alive and off all therapy.

Results by patient subgroup

Schreibe Deinen Kommentar